CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Chlorzoxazone

氯唑沙宗 杂质对照品Chlorzoxazone Impurities

29 个杂质条目29 impurity entries

本页汇总 氯唑沙宗 的 29 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 29 impurity reference standards of Chlorzoxazone. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 氯唑沙宗(Chlorzoxazone)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment, evaluation of critical method variables and stability assessment using a Box-Behnken design for the determination of organic impurities in a pharmaceutical dosage form of a centrally acting muscle relaxant drug chlorzoxazone
    Biomedical chromatography : BMC · 2024 · Ettaboina SK et al.  ·  PMID 39233497  ·  DOI
  2. 杂质研究Impurity studiesValidated specific HPLC-DAD method for simultaneous estimation of paracetamol and chlorzoxazone in the presence of five of their degradation products and toxic impurities
    Drug development and industrial pharmacy · 2020 · El-Yazbi AF et al.  ·  PMID 32894703  ·  DOI
  3. 杂质研究Impurity studiesSimultaneous determination of paracetamol, chlorzoxazone, and related impurities 4-aminophenol, 4'-chloroacetanilide, and p-chlorophenol in pharmaceutical preparations by high-performance liquid chromatography
    Journal of AOAC International · 2007 · Ali MS et al.  ·  PMID 17373439
  4. 分析方法Analytical MethodsSimultaneous Determination of Paracetamol and Chlorzoxazone in Their Combined Pharmaceutical Formulations by Reversed-phase Capillary Liquid Chromatography Using a Polymethacrylate Monolithic Column
    Journal of chromatographic science · 2018 · Salih ME et al.  ·  PMID 29920591  ·  DOI
  5. 分析方法Analytical MethodsA Simple and Rapid HPLC Method Development for Quantification of Sodium Benzoate Content in Chlorzoxazone Oral Solid Dosage Forms
    Biomedical chromatography : BMC · 2025 · Lankalapalli PK et al.  ·  PMID 39562514  ·  DOI

氯唑沙宗 —— 原料药与杂质对照品Chlorzoxazone — drug substance & impurities

共 30 个条目(含原料药本体)30 items incl. the drug substance
Chlorzoxazone structure
原料药 APIAPI
氯唑沙宗Chlorzoxazone
Chlorzoxazone
CAS No.95-25-0
Chemical FormulaC7H4ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 3 structure
3
氯唑沙宗杂质3Chlorzoxazone Impurity 3
Chlorzoxazone Impurity 3
CAS No.57718-28-2
Chemical FormulaC7H7ClN2O2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 5 structure
5
氯唑沙宗杂质5Chlorzoxazone Impurity 5
Chlorzoxazone Impurity 5
CAS No.59-49-4
Chemical FormulaC7H5NO2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 8 structure
8
氯唑沙宗杂质8Chlorzoxazone Impurity 8
Chlorzoxazone Impurity 8
CAS No.17488-25-4
Chemical FormulaC6H2Cl2N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 19 structure
19
氯唑沙宗杂质19Chlorzoxazone Impurity 19
Chlorzoxazone Impurity 19
CAS No.31499-90-8
Chemical FormulaC7H5NO2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 20 structure
20
氯唑沙宗杂质20Chlorzoxazone Impurity 20
Chlorzoxazone Impurity 20
CAS No.1635-61-6
Chemical FormulaC6H5ClN2O2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 21 structure
21
氯唑沙宗杂质21Chlorzoxazone Impurity 21
Chlorzoxazone Impurity 21
CAS No.31431-10-4
Chemical FormulaC7H8N2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 22 structure
22
氯唑沙宗杂质22Chlorzoxazone Impurity 22
Chlorzoxazone Impurity 22
CAS No.5131-58-8
Chemical FormulaC6H7N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 23 structure
23
氯唑沙宗杂质23Chlorzoxazone Impurity 23
Chlorzoxazone Impurity 23
CAS No.1502034-41-4
Chemical FormulaC6H4ClN3O
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 24 structure
24
氯唑沙宗杂质24Chlorzoxazone Impurity 24
Chlorzoxazone Impurity 24
CAS No.28443-50-7
Chemical FormulaC6H6ClNO
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 25 structure
25
氯唑沙宗杂质25Chlorzoxazone Impurity 25
Chlorzoxazone Impurity 25
CAS No.19932-85-5
Chemical FormulaC7H4BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 26 structure
26
氯唑沙宗杂质26Chlorzoxazone Impurity 26
Chlorzoxazone Impurity 26
CAS No.14733-73-4
Chemical FormulaC7H4BrNO2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 27 structure
27
氯唑沙宗杂质27Chlorzoxazone Impurity 27
Chlorzoxazone Impurity 27
CAS No.133-90-4
Chemical FormulaC7H5Cl2NO2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 28 structure
28
氯唑沙宗杂质28Chlorzoxazone Impurity 28
Chlorzoxazone Impurity 28
CAS No.2164-09-2
Chemical FormulaC11H11Cl2NO
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 29 structure
29
氯唑沙宗杂质29Chlorzoxazone Impurity 29
Chlorzoxazone Impurity 29
CAS No.10199-85-6
Chemical FormulaC6H2Cl2N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 30 structure
30
氯唑沙宗杂质30Chlorzoxazone Impurity 30
Chlorzoxazone Impurity 30
CAS No.836624-20-5
Chemical FormulaC12H6F2N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 31 structure
31
氯唑沙宗杂质31Chlorzoxazone Impurity 31
Chlorzoxazone Impurity 31
CAS No.28987-52-2
Chemical FormulaC12H8FNO3
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 33 structure
33
氯唑沙宗杂质33Chlorzoxazone Impurity 33
Chlorzoxazone Impurity 33
CAS No.3698-83-7
Chemical FormulaC6H2Cl2N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 34 structure
34
氯唑沙宗杂质34Chlorzoxazone Impurity 34
Chlorzoxazone Impurity 34
CAS No.39223-94-4
Chemical FormulaC7H3ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 36 structure
36
氯唑沙宗杂质36Chlorzoxazone Impurity 36
Chlorzoxazone Impurity 36
CAS No.532-91-2
Chemical FormulaC8H7NO3
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 37 structure
37
氯唑沙宗杂质37Chlorzoxazone Impurity 37
Chlorzoxazone Impurity 37
CAS No.1208448-95-6
Chemical FormulaC15H13NO3
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 44 structure
44
氯唑沙宗杂质44Chlorzoxazone Impurity 44
Chlorzoxazone Impurity 44
CAS No.26488-93-7
Chemical FormulaC8H8ClNO2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 45 structure
45
氯唑沙宗杂质45Chlorzoxazone Impurity 45
Chlorzoxazone Impurity 45
CAS No.103797-05-3
Chemical FormulaC11H13NO3
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 46 structure
46
氯唑沙宗杂质46Chlorzoxazone Impurity 46
Chlorzoxazone Impurity 46
CAS No.154258-05-6
Chemical FormulaC8H5Cl2NO3
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 47 structure
47
氯唑沙宗杂质47Chlorzoxazone Impurity 47
Chlorzoxazone Impurity 47
CAS No.103205-33-0
Chemical FormulaC10H11NO3
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 48 structure
48
氯唑沙宗杂质48Chlorzoxazone Impurity 48
Chlorzoxazone Impurity 48
CAS No.88-87-9
Chemical FormulaC6H3ClN2O5
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 49 structure
49
氯唑沙宗杂质49Chlorzoxazone Impurity 49
Chlorzoxazone Impurity 49
CAS No.780759-37-7
Chemical FormulaC14H6Cl2N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 50 structure
50
氯唑沙宗杂质50Chlorzoxazone Impurity 50
Chlorzoxazone Impurity 50
CAS No.610-78-6
Chemical FormulaC6H4ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 51 structure
51
氯唑沙宗杂质51Chlorzoxazone Impurity 51
Chlorzoxazone Impurity 51
CAS No.5204-46-6
Chemical FormulaC7H5Cl2NO2
Purity>95%询价On request
10mg25mg50mg100mg
Chlorzoxazone Impurity 52 structure
52
氯唑沙宗杂质52Chlorzoxazone Impurity 52
Chlorzoxazone Impurity 52
CAS No.99584-10-8
Chemical FormulaC8H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

氯唑沙宗 —— 研究文献与合成路线Chlorzoxazone — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 氯唑沙宗 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Chlorzoxazone. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Development, evaluation of critical method variables and stability assessment using a Box-Behnken design for the determination of organic impurities in a pharmaceutical dosage form of a centrally acting muscle relaxant drug chlorzoxazone
    Ettaboina SK, Nannapaneni S, Jeedimalla N, et al. · Biomedical chromatography : BMC · 2024 · 被引 10cited 10
  2. Validated specific HPLC-DAD method for simultaneous estimation of paracetamol and chlorzoxazone in the presence of five of their degradation products and toxic impurities
    El-Yazbi AF, Guirguis KM, Bedair MM, et al. · Drug development and industrial pharmacy · 2020 · 被引 5cited 5
  3. Stability-indicating TLC-densitometric method for simultaneous determination of paracetamol and chlorzoxazone and their toxic impurities
    Abdelaleem EA, Abdelwahab NS · Journal of chromatographic science · 2013 · 被引 5cited 5
  4. Simultaneous determination of paracetamol, chlorzoxazone, and related impurities 4-aminophenol, 4'-chloroacetanilide, and p-chlorophenol in pharmaceutical preparations by high-performance liquid chromatography
    Ali MS, Rafiuddin S, Ghori M, et al. · Journal of AOAC International · 2007 · 被引 12cited 12
  5. Traditional versus advanced chemometric models for the impurity profiling of paracetamol and chlorzoxazone: Application to pure and pharmaceutical dosage forms
    Saad AS, AlAlamein AMA, Galal MM, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2018 · 被引 7cited 7
  6. Green Constant-wavelength Concurrent Selective Fluorescence Method for Assay of Ibuprofen and Chlorzoxazone in Presence of Chlorzoxazone Degradation Product
    Abdallah NA, Fathy ME, Tolba MM, et al. · Journal of fluorescence · 2023 · 被引 3cited 3

合成路线文献Synthetic-route papers

  1. Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: design, synthesis, pharmacological investigations and docking studies
    Abdel-Azeem AZ, Abdel-Hafez AA, El-Karamany GS, et al. · Bioorganic & medicinal chemistry · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

氯唑沙宗 杂质谱研究要点Chlorzoxazone — impurity profiling notes

下面这些是拿到 氯唑沙宗 的 30 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 30 impurity entries for Chlorzoxazone, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances